Summit Securities Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
Other funds holding ABBV
Summit Securities Group's ABBV Position: Q3 2026 in Review
Summit Securities Group reduced its AbbVie (ABBV) stake by 87% in Q3 2026, selling an estimated $271K and leaving 152 shares worth $39.8K. The position accounts for ﹤0.01% of the portfolio, ranked #607.
Summit Securities Group first reported a position in ABBV in Q2 2013 and has held it in 50 quarters since. The position peaked at $14.1M in Q4 2021. 4,284 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.
- Summit Securities Group held 152 shares of AbbVie worth $39.8K as of Q3 2026.
- Summit Securities Group sold 1,058 AbbVie shares in Q3 2026, an estimated $271K.
- AbbVie made up ﹤0.01% of Summit Securities Group's portfolio in Q3 2026, its #607 holding.
- Summit Securities Group first reported a position in AbbVie in Q2 2013 and has held it in 50 quarters since.
- Summit Securities Group's AbbVie position peaked at $14.1M in Q4 2021.
- 4,284 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.
Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.